• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    SciSparc Ltd. - Ordinary Shares (NQ:SPRC)

    6.710 -0.180 (-2.61%)
    Streaming Delayed Price Updated: 12:32 PM EDT, Aug 6, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about SciSparc Ltd. - Ordinary Shares

    < Previous 1 2 3 4 5 6 7 Next >
    News headline image
    SciSparc: Subsidiary NeuroThera Labs Launches Phase IIb Clinical Trial at Yale Child Study Center for First-of-its-kind Treatment for Tourette Syndrome
    From SciSparc Ltd
    Via GlobeNewswire
    News headline image
    SciSparc: Subsidiary NeuroThera Labs' Quantum Platform Demonstrates Complete End-to-End Hybrid Quantum-Classical Workflow for Clinical Data Analytics
    From SciSparc Ltd
    Via GlobeNewswire
    News headline image
    SciSparc: Subsidiary NeuroThera Labs Advances its Quantum Platform for Clinical Data Analytics on a Platform of an S&P 500 company
    From SciSparc Ltd
    Via GlobeNewswire
    News headline image
    SciSparc Announces Decision to Target the Agentic AI Market; Forms Scientific Advisory Board for Artificial Intelligence and Cybersecurity
    From SciSparc Ltd
    Via GlobeNewswire
    News headline image
    SciSparc: NeuroThera Labs Announces Initiation of Phase IIb Clinical Trial at Hannover Medical School in Germany for Innovative Treatment of Tourette Syndrome
    From SciSparc Ltd
    Via GlobeNewswire
    News headline image
    SciSparc: Subsidiary NeuroThera Labs Completed Acquisition of CliniQuantum
    From SciSparc Ltd
    Via GlobeNewswire
    News headline image
    Neurothera Labs Inc. Announces Closing Of Acquisition Of Majority Stake In Cliniquantum Ltd.
    Toronto, Ontario – June 3, 2026 – TheNewswire – NeuroThera Labs Inc. (TSXV: NTLX) (the “Company” or “NeuroThera”), a clinical-stage biotech company and a majority-owned subsidiary of SciSparc Ltd.... 
    Via TheNewswire.com
    Topics Intellectual Property
    News headline image
    SciSparc: Subsidiary NeuroThera Labs Received Conditional Regulatory Approval for Acquisition of CliniQuantum
    From SciSparc Ltd
    Via GlobeNewswire
    News headline image
    SciSparc: NeuroThera Labs- Clearmind Medicine Collaboration Leads to Patent Application for Depression Therapy
    From SciSparc Ltd
    Via GlobeNewswire
    News headline image
    Clearmind Medicine Announces Hong Kong Patent Filing for Depression Therapy
    From Clearmind Medicine Inc.
    Via GlobeNewswire
    News headline image
    SciSparc: NeuroThera Labs Announces Publication of International Patent in Collaboration with Clearmind Medicine for Novel Therapy Targeting Weight Loss and Fatty Liver Disease
    From SciSparc Ltd
    Via GlobeNewswire
    News headline image
    SciSparc: Subsidiary NeuroThera Labs (75%) Signs Definitive Agreement to Acquire Majority Stake in CliniQuantum, Innovator in Quantum-based Clinical trails
    From SciSparc Ltd
    Via GlobeNewswire
    News headline image
    Clearmind Medicine Announces Publication of International Patent for Novel Therapy Targeting Weight Loss and Fatty Liver Disease
    From Clearmind Medicine Inc.
    Via GlobeNewswire
    News headline image
    SciSparc Announces 1-for-9 Reverse Share Split
    From SciSparc Ltd
    Via GlobeNewswire
    News headline image
    SciSparc: NeuroThera Labs Granted U.S. Patent for Cannabinoid Technology to Overcome Antimicrobial Resistance such as MRSA
    From SciSparc Ltd
    Via GlobeNewswire
    News headline image
    SciSparc Successfully Completes Acquisition of IP Portfolio, Advances Toward Immediate Commercialization
    From SciSparc Ltd
    Via GlobeNewswire
    News headline image
    SciSparc Signs Definitive Agreement to Acquire a Treasury of Patents for the Endoscope Market- Entering Multi-Billion Dollar Opportunity
    From SciSparc Ltd
    Via GlobeNewswire
    News headline image
    SciSparc Announces Receipt of Nasdaq Notification of Minimum Stockholders’ Equity Non-Compliance
    From SciSparc Ltd
    Via GlobeNewswire
    News headline image
    SciSparc: Neurothera Labs Granted Patent by Israeli Patent Office for its Proprietary Opioid-Based Patent Family to Enhance Pain Relief and Reduce Side Effects
    From SciSparc Ltd
    Via GlobeNewswire
    News headline image
    SciSparc: Neurothera Labs Signs Non-Binding Term Sheet to Acquire Majority Stake in a Quantum Algorithm Bio Data Analysis Company
    From SciSparc Ltd
    Via GlobeNewswire
    News headline image
    SciSparc Plans on Entering the Multi-Billion-Dollar GERD Device Market with Acquisition of an Approved IP Portfolio
    From SciSparc Ltd
    Via GlobeNewswire
    News headline image
    SciSparc to Acquire Treasury of Patents for Innovative Medical Endoscopy Systems
    From SciSparc Ltd
    Via GlobeNewswire
    News headline image
    SciSparc: Neurothera Labs Announces Israeli Patent Application in Collaboration with Clearmind Medicine for Novel Non-Hallucinogenic Neuroplastogen Treatment for Depression
    From SciSparc Ltd
    Via GlobeNewswire
    News headline image
    Clearmind Medicine Files Israeli Patent for Novel Non-Hallucinogenic Neuroplastogen Treatment for Depression
    From Clearmind Medicine Inc.
    Via GlobeNewswire
    News headline image
    SciSparc Announces Closing of the Acquisition of a Publicly Traded Company on the TSXV to which it transferred its Advanced Clinical Stage Pharmaceutical Portfolio
    From SciSparc Ltd
    Via GlobeNewswire
    News headline image
    SciSparc Announces Closing of the Sale to N2OFF of Majority-Owned Subsidiary MitoCareX, Advancing Drug Discovery for Resistant Cancers Including Pancreatic and Non-Small Cell Lung Cancer
    From SciSparc Ltd
    Via GlobeNewswire
    News headline image
    SciSparc Targets Quantum-Powered 3D Protein Modeling Technology to Revolutionize AI Drug Discovery
    From SciSparc Ltd
    Via GlobeNewswire
    News headline image
    Clearmind Medicine Announces Publication of U.S. Patent Application Targeting Binge Behavior Disorders
    From Clearmind Medicine Inc.
    Via GlobeNewswire
    News headline image
    SciSparc-Clearmind Collaboration Leads to Publication of U.S. Patent Application Targeting Binge Behavior Disorders
    From SciSparc Ltd
    Via GlobeNewswire
    News headline image
    SciSparc Enters into Definitive Agreement for the Acquisition of a Publicly Traded Company on the TSXV to which it will transfer its Advanced Clinical Stage Pharmaceutical Portfolio
    From SciSparc Ltd
    Via GlobeNewswire
    < Previous 1 2 3 4 5 6 7 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.